Substance-Related Disorders — Treatment Adherence in Substance Users
Citation(s)
Albiach C, Llinares MC, Palau C, Santos P Adherencia en heroinómanos: la potencia predictiva de los estadios de cambio evaluados durante la admisión al tratamiento. Adicciones. 2000;12(2):225-234.
Albiach C, Palau C, Llinares C, Santos P Estudio sobre la adherencia al tratamiento en sujetos con adicción a diferentes sustancias que acuden a servicios ambulatorios. En: V Encuentro Nacional sobre drogodependencias y su enfoque comunitario; 1998; Chiclana de la Frontera, Cádiz, p. 57-70.
Herrera JM, Barberán M, Yumar T La adherencia al tratamiento en una Unidad de Atención a las Drogodependencias (UAD). Trabajo Social y Salud. 2008; (61):155-182.
Olmos-Espinosa R, Madoz-Gúrpide A, Ochoa E Situación al año de los adictos a opiáceos que siguieron tratamiento ambulatorio tras desintoxicación hospitalaria. Adicciones. 2001;13(2):173-8.
Silva Lento AF, Cerqueira AM, Rocha Costa OC Programa de deshabituación. ¿Cuáles son los factores que llevan al dropout? Revista española de drogodependencias. 2004; (1):62-70.
Sirvent C, Villa M, Blanco P, Rivas C, Linares MP, Quintana L Predicción del abandono (vs. éxito) terapéutico en adicciones. (Presentación del cuestionario VPA-30 (c Sirvent, 2009), de variables predictores de abandono y adherencia al tratamiento en adicciones). Interpsiquis 2010.
Zamora YR Predicción del abandono del tratamiento en adictos mediante el cuestionario VPA-30. Revista del Hospital Psiquiátrico de La Habana. 2014;11(2).
Factors Associated With Treatment Adherence in Substance Users
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
